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An Update on the Clinicopathologic Features and Pathologic
Diagnosis of Hepatitis E in Liver Specimens
Daniela Lenggenhager, MD and Achim Weber, MD
Abstract: Infection with the hepatitis E virus (HEV) is globally seen
a leading cause of hepatitis. Now increasingly recognized also in
industrialized countries, hepatitis E constitutes a signiﬁcant health
problem worldwide. The patient’s immune status determines the
clinical course and histopathology of hepatitis E. In immuno-
competent patients, hepatitis E usually follows an asymptomatic or
subclinical course, but may also present with acute hepatitis. In
contrast, immunocompromised patients may develop chronic hep-
atitis, and patients with preexisting liver diseases are at risk for liver
decompensation with potentially fatal outcome. Whereas patholo-
gists only occasionally encounter liver biopsies from immuno-
competent individuals with hepatitis E, they are more likely exposed
to biopsies from patients with preexisting liver disease or immu-
nocompromised individuals. Histopathologic hallmarks of hepatitis
E in immunocompetent patients comprise lobular disarray, lobular,
and portal inﬂammation, as well as hepatocyte necrosis of varying
extend and regeneration. Thus, it is similar to acute non–E viral
hepatitis, yet further differential diagnoses include autoimmune
hepatitis and drug-induced liver injury. Histopathologic ﬁndings of
hepatitis E in preexisting liver disease are determined by the
underlying pathology, but may be more severe. Histopathologic
presentation of hepatitis E in immunocompromised patients is
highly variable, ranging from minimal active hepatitis to chronic
hepatitis with severe activity and progressive ﬁbrosis. Taken
together, the variability of the histologic features depending on the
clinical context and the overlap with other liver diseases make the
histopathologic diagnosis of hepatitis E challenging. Immunohis-
tochemistry for HEV open reading frame 2 protein and molecular
testing for HEV RNA are useful tissue-based ancillary tools.
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S ince hepatitis E was recognized as a distinct disease in1980, it was considered an acute, self-limiting, water-
borne infection that was largely restricted to developing
countries, where it occurred in epidemics and had a dismal
prognosis in pregnant women.1 Nearly a decade ago, it
became clear that hepatitis E virus (HEV) infection is more
common in industrialized countries than initially thought,
with surprisingly high seroprevalence, for example, in the
United States of America up to 21%,2 in the United King-
dom up to 25%,3 in France on average 30% and up to 86%
in a hyperendemic region in the southwest of France.4,5 In
developed countries, HEV is largely transmitted zoonotically
by the consumption of uncooked or undercooked meat—in
most cases pork or game meat.6 Although HEV infection in
this setting usually takes an asymptomatic and self-limiting
course in immunocompetent persons, it can become a serious
health risk with possible acute liver failure in patients with
preexisting liver disease, and may take a chronic course in
immunocompromised patients.7–10
HEV is a small, quasienveloped, positive-strand RNA
virus of the family Hepeviridae, genus Orthohepevirus.11,12
Its 7.2 kb genome has 3 open reading frames (ORF) coding
for the viral replicase (ORF1), the capsid protein (ORF2),
and a small phosphoprotein required for the secretion of
viral particles (ORF3). ORF2 and ORF3 have an intra-
genotypically and intergenotypically highly conserved,
extensively overlapping gene sequence, which make this
sequence an ideal target region for molecular testing.11,13,14
As the ORF2 capsid protein is highly immunogenic, it is the
preferred antigen for vaccine development. Probably for
the same reason, it also constitutes a strong candidate for
the development of tissue-based diagnostic tests, such as
immunohistochemistry (IHC).15,16
Currently, 5 HEV strains are distinguished which infect
humans (Table 1): genotypes (GT) 1, 2, 3, 4, and most
recently 7 with variable geographic distribution.17–21 GT1
and GT2, mainly occur as waterborne epidemic outbreaks
in regions such as Asia, Africa, and Central America and
seem to be restricted to humans.21,22 In contrast, the other 3
GTs represent zoonotic infections, mainly transmitted
through the consumption of uncooked or undercooked
contaminated animal products.23,24 GT3, occurring world-
wide, and GT4, occurring in China and Southeast Asia,
have been detected in a wide range of species, such as
domestic pigs, game animals, but also bivalves and
oysters.25 Recently GT7 was detected in feces of camel
species in the Middle East, North and East Africa, and
China, with some limited evidence of HEV GT7 trans-
mission to humans from the consumption of camel meat and
milk.20,26,27
Clinical manifestation of hepatitis E is highly variable
and dependent on the patient’s immune status (Table 1). In
immunocompetent patients—irrespective of the GT—the
majority of HEV infections remain asymptomatic. If clin-
ically apparent, HEV infection in this setting mostly presents
as an acute, self-limiting disease, mainly diagnosed by serologic
testing. With the exception of pregnant women, acute liver
failure due to acute HEV infection in immunocompetent
patients may occur, but is extremely rare.18,28 However, in
patients with preexisting liver disease such as (non) alcoholic
steatohepatitis, acute decompensation with fatal outcome of
HEV infection is more frequently observed.7 In immunocom-
promised patients, HEV infection can be easily missed. The
usually minimal active hepatitis with no or only unspeciﬁc
clinical symptoms and only slight and undulating elevation of
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transaminases can molder unnoticed, and thus take a chronic
course with the development of liver ﬁbrosis.8–10
Clinical suspicion of acute hepatitis E can be veriﬁed by
laboratory tests, either by the detection of HEV-speciﬁc IgM
antibodies in blood, conﬁrmed by showing IgG antibody levels
rising over time, or by molecular detection of HEV RNA, in
blood during a relatively short viremic period of about 3 weeks,
and in stool samples, in which the virus is detectable for an
additional 2-week period.18,22 In general, antibody-based sero-
logical testing for HEV is variably sensitive and speciﬁc—
especially in immunocompromised patients—and thus remains
less robust compared with molecular testing.29–31 Detection of
HEV RNA is not only important for establishing and/or con-
ﬁrming the diagnosis of hepatitis E, but can also be helpful for
the monitoring of HEV viremia in case of chronic hepatitis E.
Histopathologic diagnosis of HEV infection is chal-
lenging as histologic ﬁndings are highly variable and overlap
with other causes of hepatitis.10,32–35 Although hepatitis E
diagnosis can be readily made by serologic tests, patholo-
gists are routinely confronted with cases in which serological
testing either has not been performed, or results are not yet
available. Furthermore, given the comparatively short
viremic period, a negative HEV RNA blood test does not
deﬁnitively exclude a recent infection.
HEPATITIS E VIRUS INFECTION IN
IMMUNOCOMPETENT PATIENTS
Acute Epidemic Hepatitis E Virus Infection
Although acute hepatitis E in developing countries is
usually a clinical diagnosis, liver histology has been docu-
mented in some large epidemic outbreaks, including 1 in
Delhi, India in 1955/1956,36 and 1 in Kashmir in the late
1970.37 A more recent study based on 11 postmortem
biopsies taken from patients with fatal acute fulminant
hepatitis E compared the histologic ﬁndings with those
observed in fulminant hepatitis B.38 Furthermore, there are
occasional case reports on travel-related hepatitis E—for
example, following visits to India, Asia, Africa or South
America—that comment on histologic changes.39,40 In
summary, the histologic ﬁndings described in all these
studies are comparable with those found in hepatitis A with
either a more inﬂammatory (so-called “standard” or “clas-
sical”) pattern, or a more cholestatic (so-called “obstruc-
tive”) variant. In detail, the following histopathologic
changes have been described: a varying degree of mixed
portal and lobular inﬂammation, more or less prominent
Kupffer cell inﬁltrates as well as a variable extent of liver
cell necrosis, ranging from single-cell apoptosis to more
TABLE 1. Epidemiology and Clinical Setting of Hepatitis E Virus Infection
Immunocompetent Patients
Patients With Preexisting
Liver Disease
Immunocompromised
Patients
Acute Epidemic
Infection
Acute Autochthonous
Infection
Acute on Chronic Liver
Disease Chronic-active Hepatitis
Genotypes/
Hosts
GT1, GT2/humans only GT3, GT4/humans and
animals (pigs, game animals,
mussels, etc.)
All GT/humans and animals
(pigs, game animals, mussels,
etc.)
GT3, GT4/humans and
animals (pigs, game animals,
mussels, etc.)
GT7*/camel species (humans)
Global
distribution
GT1: Asia, Africa,
Central America
GT2: mainly Africa and
Central America
GT3: worldwide
GT4: Southeast Asia, China
Worldwide GT3: worldwide
GT4: Southeast Asia, China
GT7: Middle East, North and
East Africa, and China
Transmission Fecally; orally mostly by
contaminated
drinking water
Mainly consumption of
uncooked or undercooked
contaminated meat (pork,
game, others); rarely blood
products
Contaminated drinking water or
consumption of uncooked or
undercooked contaminated
meat (pork, game, others)
Mainly consumption of
uncooked or undercooked
contaminated meat (pork,
game, others)
Patient group Younger patients;
In industrialized
countries: travel
returnees from
endemic regions
Older patients; individuals
which consume frequently
pork or game meat
Older patients (male> female);
frequently with alcohol
disease
Any age; solid organ
transplant recipients, HIV
+patients, patients with
hematologic and
rheumatologic diseases
Clinical
presentation
Ranging from
asymptomatic to
fulminant
Ranging from asymptomatic to
symptomatic
Acute deterioration of a
preexisting chronic liver
disease
Rarely symptomatic
ALT levels High ALT levels, usually > 1000 IU/L at time of diagnosis Usually ALT levels
<< 1000 IU/L
Clinical course Usually self-limiting
disease with viral
clearance;
subgroup: pregnant
women: higher risk
for fatal outcome
(particularly in third
trimester)
Usually self-limiting disease
with viral clearance
Decompensation of the
underlying liver disease with
high risk of fatal outcome
High failure of viral clearance
with possible development
of chroniﬁcation and
progressive ﬁbrosis/cirrhosis
*GT7: only 1 case report of chronic hepatitis in a liver-transplanted human being from the United Arab Emirates who consumed regularly camel meat
and milk.
ALT indicates alanine aminotransferase; GT, genotype; HIV, human immunodeﬁciency virus.
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severe forms with bridging and subtotal hepatic necrosis. In
the more cholestatic variants, ballooning degeneration,
rosettes’ formation as well as hepatocellular and intra-
canalicular bilirubinostasis were also frequently observed. In
severe cases with bridging or (sub)total necrosis and pro-
gressive ductular proliferation, even bile plugs within dilated
cholangioles have been reported. The most important dif-
ferential diagnoses regarding the pattern of acute (choles-
tatic) hepatitis are non–E viral infections (eg, hepatitis A
virus, EBV), autoimmune hepatitis, and drug-induced liver
injury (Table 2). Pathologists in industrialized countries are
not only confronted with liver biopsies performed on travel-
related cases of hepatitis E, but also with liver explants in
the setting of liver transplantation due to rare cases of acute
liver failure following imported HEV infection, in particular
in young women.28,34,39 Liver explants usually are small and
lightweight due to parenchymal collapse following pan-
lobular necrosis. Typical histopathologic features are bilir-
ubinostasis, massive clearing by ceroid-laden macrophages,
and extensive ductular reaction reﬂecting futile regener-
ation. In such a setting, the most important differential
diagnoses are drug-induced liver injury and toxins, infec-
tions with non–E viruses (eg, HBV, adenovirus) as well as
autoimmune hepatitis and metabolic diseases such as Wil-
sons’ disease (Table 2).
Histologic ﬁndings are illustrated in Figure 1 by 2 cases
of travel-related hepatitis E of varying severity, both HEV
GT 1 infections and occurring after a trip to India:
Figure 1A shows the liver biopsy of a 50-year-old man who
developed acute self-limiting hepatitis E with lobular dis-
array as well as portal and lobular inﬂammation. IHC for
HEV ORF 2 protein displayed cytoplasmic and nuclear
positivity in scattered hepatocytes as shown in the insert.39
Figure 1B illustrates the histologic ﬁndings in a liver explant
from a 26-year-old female patient who developed fulminant
liver failure with panlobular necrosis, parenchymal collapse,
and ducutular proliferation as a sign of futile regeneration as
well as some portal inﬂammation. Whereas HEV was still
detectable by tissue-based RT-PCR,34 immunohistochem-
ical detection using a HEV ORF 2 antibody was not pos-
sible in this subtotally necrotic tissue.16
Acute Autochthonous Hepatitis E Virus Infection
Although the awareness of autochthonous HEV
infection—mostly with GT3—occurring in industrialized
countries has increased during the last 10 years, reports on
histologic features of acute autochthonous HEV infection in
immunocompetent patients are still rather rare, mainly
because the diagnosis is usually based on serology. If a liver
biopsy is performed, this is usually done early in the diag-
nostic process, when the list of differential diagnoses is still
long, and results of serological testing are not yet available.
Histopathologic ﬁndings of acute autochthonous HEV
infection with GT3 are similar to those described in acute
hepatitis with HEV GT1. Immunocompetent individuals
usually show a prominent lobular disarray with rosettes’
TABLE 2. Histologic Findings and Most Important Differential Diagnoses of Hepatitis E Virus Infection
Immunocompetent Patients
Patients With Preexisting
Liver Disease Immunocompromised Patients
Acute Epidemic or
Autochthonous Infection Acute on Chronic Liver Disease Chronic-active Hepatitis
Histologic
features
Acute hepatitis
mixed lobular and portal inﬂammation,
interface activity
Lobular disarray, rosettes’ formation and
ballooned hepatocytes
Increased number of Kupffer cells
Variable degree of hepatocyte necrosis
(mostly spotty necrosis, but bridging
necrosis or only single apoptotic
hepatocytes also possible)
Expanded portal tracts with mixed
inﬂammation
cholangitis and ductular reaction
Hepatocytic and canalicular bilirubinostasis
Subgroup: fulminant liver failure
panlobular necrosis
parenchymal collaps
bilirubinostasis
clearing by ceroid-laden macrophages
Cirrhosis
Ballooned hepatocytes
+/−Mallory-Denk hyaline
necroinﬂammatory inﬁltrates
Kupffer cell aggregates
Siderosis
variable degree of hepatocyte
necrosis
Cholangitis
cholestasis/bilirubinostasis
Portal-based mononuclear
inﬂammation (predominantly
lymphocytes)
Lacking or low interface activity
Variable degree of hepatocyte necrosis
(mostly single scattered apoptotic
hepatocytes)
Fibrosis development
Most important
differential
diagnoses
Non–E hepatotropic viruses (eg, HAV)
Nonhepatotropic viruses (eg, EBV)
autoimmune hepatitis
drug-induced liver injury and toxins
Subgroup: fulminant liver failure
Drug-induced liver injury and toxins
Non–E hepatotropic viruses (eg, HBV)
nonhepatotropic viruses (eg, adenovirus)
Autoimmune hepatitis
Metabolic diseases (eg, Wilsons’ disease)
Decompensation of underlying
chronic liver disease, for
example, ASH or NASH
Non–E hepatotropic viruses (HBV,
HCV)
autoimmune hepatitis
In liver transplant patients:
acute cellular rejection
recurrence of initial viral hepatitis (eg,
HCV, HBV)
drug-induced changes by
immunosuppressive therapy itself
ASH indicates alcoholic steatohepatitis; HAV, hepatitis A virus; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis.
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formation and a variable number of ballooned hepatocytes
as well as a variable degree of necrosis, ranging from usually
spotty necrosis to pericentral and even panlobular
necrosis.32–35,41 Portal tracts are usually considerably
expanded with bile duct proliferations and a mixed inﬂam-
matory cell inﬁltrate comprising lymphocytes, plasma cells,
histiocytes, and also many neutrophils and eosinophils,
which can involve the bile duct epithelium.32,41 Malcolm and
colleagues describe a variable degree of hepatocellular and
canalicular bilirubinostasis and a zonal distribution pattern
of inﬂammatory cells in the portal tracts. At the periphery/
interface they observed more polymorphs, while a lympho-
histiocytic component (including plasma cells) was more
pronounced in the center of the portal tract.41 Drebber et al33
pointed in addition at the absence of ﬁbrosis, which is a
feature of chronic hepatitis. Thus, the differential diagnosis
of an acute autochthonous HEV infection in immuno-
competent patients is basically the same as for acute epidemic
HEV infection (Table 2).
Histologic ﬁndings of a typical acute autochthonous
HEV GT3 infection in an immunocompetent patient are
illustrated in Figures 2A–C. The liver biopsy of a 67-year-old
female patient with acute self-limiting hepatitis displays
lobular disarray as well as portal and lobular inﬂammation.
Besides scattered apoptotic hepatocytes, many prominent
macrophages/activated Kupffer cells are distinguishable,
even focally clustered, indicating extensive recent piecemeal
necrosis. No signs of underlying chronic liver disease were
observable.
HEPATITIS E VIRUS INFECTION IN PATIENTS
WITH PREEXISTING CHRONIC LIVER DISEASES
Patients, with preexisting (chronic) liver disease who are
infected with HEV, are prone to develop acute on chronic liver
failure. Already a decade ago, this unfavorable course has been
well documented for HEV infections occurring in both,
developing and industrialized countries.7,32,42 In a large study
from India, a panoply of different underlying chronic liver
diseases has been identiﬁed: from chronic HBV and hepatitis C
virus infections over alcoholic liver disease to metabolic dis-
eases such as Wilsons’ disease and hemochromatosis, and even
perfusion-related liver diseases.43 In industrialized countries,
patients with cirrhosis due to alcoholic and eventually non-
alcoholic steatohepatitis may represent the largest patient
groups that develop a rapid decompensation on autoch-
thonous HEV infection.40,44–46 Furthermore, it seems that
cirrhotic patients are prone to be infected with HEV, but
whether overconsumption of alcohol in itself is associated with
increased susceptibility to acute hepatitis E is still unclear.47
Histopathologic ﬁndings of HEV infection in this set-
ting reveal acute damage in addition to an underlying
ﬁbrotic/cirrhotic process. Histologic ﬁndings in the majority
of the above-mentioned studies are described as follows:
liver parenchyma with advanced ﬁbrosis or cirrhosis,
marked necroinﬂammatory activity with ballooned hep-
atocytes with or without Mallory-Denk hyaline, surrounded
by neutrophils, Kupffer cell aggregates with siderosis, scat-
tered apoptotic hepatocytes, but also conﬂuent necrosis as
well as prominent acute cholangitis and cholestasis. All
those histologic features are nonspeciﬁc, and in the context
of an established alcohol-related cirrhosis, they can easily be
mistaken for acute alcoholic hepatitis.48 As the diagnosis of
acute hepatitis E infection in patients with chronic liver
disease is often overlooked, it is important for pathologists
as well as for clinicians to have HEV infection on their list of
differential diagnoses, as an early diagnosis can prompt
early therapy with the antiviral substance ribavirin.49
Histologic ﬁndings of an acute autochthonous HEV
GT3 infection in a patient with preexisting chronic liver
disease are illustrated in Figures 2D–F. The liver biopsy of a
66-year-old female patient with cirrhosis on nonalcoholic
steatohepatitis shows nodular liver parenchyma with
rosettes’ formation and steatosis, surrounded by broad
ﬁbrotic septae. The hepatocytes are ballooned with Mallory-
Denk hyaline in the cytoplasm.
HEPATITIS E VIRUS INFECTION IN
IMMUNOCOMPROMISED PATIENTS
Following a seminal study from France published in
2008,8 there were several papers reporting that HEV—
mostly GT3—can cause chronic infections in immunocom-
promised patients with signiﬁcant morbidity and mortality.
The studies comprised mostly solid organ transplant
recipients,8,50–53 and human immunodeﬁciency virus-
positive patients,3,54 but also included patients with hema-
tological malignancies receiving chemotherapy or stem
cell transplantation,55,56 and patients treated with immu-
nosuppressive drugs for other, for example, rheumatologic
FIGURE 1. Histopathology of endemic (travel-related) hepatitis E
(HEV genotype 1 infection), both cases occurring following a trip
to India. A, Liver biopsy of a male patient with acute self-limiting
hepatitis E. Note lobular disarray, portal, and lobular inflammation
as well as Kupffer cell hyperplasia (black arrowheads). Scale
bar: 250 μm. Insert: immunohistochemistry for HEV open reading
frame 2 protein displaying hepatocytes with predominately
nuclear reactivity (black arrowhead), predominately cytoplasmic
reactivity (gray arrowhead), and no reactivity (white arrowhead).
Scale bar: 50 μm. B, Liver explant of a young female patient with
travel-related acute hepatitis E resulting in fulminant liver failure.
Note panlobular necrosis, predominantly periportal inflammation,
and futile regeneration. Scale bar: 250 μm. HEV indicates hepatitis
E virus.
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FIGURE 2. A–F, Histopathology of autochthonous hepatitis E (HEV genotype 3 infection). A–C Case of an immunocompetent individual.
A, Liver biopsy of a female patient with acute self-limiting hepatitis E. Note lobular disarray as well as portal and lobular inflammation.
Scale bar: 250 μm. B, Lobular inflammation and increased number of prominent pigmented Kupffer cells (black arrowheads). Scale bar:
100 μm. C, Scattered hepatocyte apoptosis (black arrowhead). Scale bar: 50 μm. D–F, Case of a patient with underlying chronic liver
disease. D, Liver biopsy of a female patient with cirrhosis due to nonalcoholic steatohepatitis and additional acute hepatitis E. Low power
view revealing broad bridging fibrotic septae, parenchymal nodularity and steatosis. Masson trichrome stain. Scale bar: 1mm. E,
Hepatocytes with ballooning (gray arrowhead) and Mallory-Denk hyaline (black arrowhead). Scale bar: 100 μm. F, Rosettes formation
(black arrowheads). Sale bar: 50 μm. HEV indicates hepatitis E virus.
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diseases.56 The risk of chroniﬁcation of HEV infection in
solid organ transplant recipients may depend on the
immunosuppressive drug. Thus, the percentage reported in
different studies ranges considerably, between 21% and
66%.9 In this clinical setting, untreated chronic HEV hep-
atitis can progress rapidly to cirrhosis, as reported by several
of the above-mentioned studies. Recently, it was suggested
that in the setting of organ transplantation, chronic HEV
infection should be considered when HEV replication per-
sists for > 3 months. This concept is in contrast to the usual
deﬁnition of chronic hepatitis (virus replication of
> 6 months), as in this particular patient group no sponta-
neous clearance of HEV was observed between 3 and
6 months after an acute infection.57 As the differential
diagnosis of elevated liver enzymes in immunocompromised
patients is broad, the threshold to perform a liver biopsy is
rather low. Especially in liver-transplanted patients, acute
cellular rejection has to be evaluated histologically. Liver
damage in immunocompromised patients has been reported
to be generally less acute and less extensive than in immu-
nocompetent individuals, with often a subclinical/anicteric
course and only a slight undulating elevation of trans-
aminases over time.8,35,50,58,59 This also explains why HEV
infection in this patient group is easily overlooked for weeks
or even months.
Histologic ﬁndings in chronic-active HEV infections
are similar to those observed in chronic-active viral hepatitis
B or C. They include lobular activity with variable degree of
piecemeal necrosis, mainly presenting as single-cell apop-
tosis without signiﬁcant inﬂammation or hepatocytes’ bal-
looning, portal lymphocytic inﬁltrates of variable degree
without signiﬁcant interface activity and eventually devel-
opment of ﬁbrosis.8,50 In our own cases, we noticed a
generally lower degree of lobular disarray and a lack of
cholestasis or bilirubinostasis, again indicative of less
extensive damage.10 Development of ﬁbrosis has been
documented in detail in one of our patients who had
developed HEV infection after liver transplantation for
cirrhosis due to alpha-1-antitypsin deﬁciency. Over a period
of > 3 years, he developed progressive liver ﬁbrosis which
was documented in a series of 5 liver biopsies. The same case
also illustrates how variable the inﬂammatory activity can
be during HEV infection, ranging from nearly nonreactive
to prominent inﬂammatory activity.10 In immunocompro-
mised patients, the most important differential diagnoses are
other viral infections such as HBV and hepatitis C virus
infection, as well as autoimmune hepatitis. In liver trans-
plant recipients, the most important differential diagnoses
are acute cellular rejection and newly acquired or recurrent
non–E viral hepatitis (Table 2). Furthermore, histopatho-
logic ﬁndings can also be mistaken to be related to the
immunosuppressive therapy itself.8
Histologic ﬁndings at different timepoints of an
autochthonous HEV GT3 infection after liver trans-
plantation in a 66-year-old patient are illustrated in Figure 3.
The liver biopsy taken almost 3 years after liver trans-
plantation showed moderate portal and lobular inﬂamma-
tion with some lobular disarray and numerous apoptotic
hepatocytes. Furthermore, portal, periportal, and pericentral
ﬁbrosis was detectable by Sirius red staining. However, the
liver biopsy taken in an early phase after HEV infection
displayed unremarkable portal tracts with lack of inﬂam-
matory inﬁltrates, and only few scattered apoptotic
hepatocytes.10 HEV ORF 2 protein IHC can be very helpful,
as illustrated in another case.
ANCILLARY TOOLS FOR THE HISTOPATHOLOGIC
DIAGNOSIS OF HEPATITIS E
As outlined above, histopathologic features of HEV
infection are nonspeciﬁc and overlap substantially with
those of hepatitis of other etiology. Thus, ancillary tools are
required for making a deﬁnitive histopathologic diagnosis.
Reliable diagnostic tools in the hands of pathologists are
still polymerase chain reaction-(PCR) based molecular tests,
targeting the intragenotypically and intergenotypically
highly conserved ORF 2 and 3 gene region. By modifying
those tests for the detection of HEV RNA in formalin-ﬁxed
parafﬁn-embedded liver tissues, they have been successfully
applied to liver specimens by several pathology laboratories,
including ourselves.10,33–35 However, PCR methods are not
available in all pathology laboratories.
Naturally, in situ techniques such as in situ hybridization
(ISH) and IHC, are convenient ancillary tools for pathologists.
Recently, the literature about in situ localization of HEV in
liver tissues has been growing. Until 2016, only a few studies on
the detection of HEV RNA and HEV proteins in the liver—
including primates’ and swine liver as well as humanized mice—
were reported.60–64 In a recent study, Prost et al35 performed
HEV ISH in a substantial collective of human liver biopsies.
They concluded that in situ RNA testing is very speciﬁc, but less
sensitive (61%) compared with tissue-based PCR testing (91%).
However, depending on the clinical setting and the equipment
of a pathology laboratory, ISH can have its diagnostic utility.
In our own study on in situ localization of HEV in the
human liver, a HEV antibody against the capsid protein ORF 2
showed the most reliable results with a high speciﬁcity rate and a
sensitivity rate of 70%, detecting 82% of the cases tested positive
by a tissue-based molecular PCR method.65 As we found ORF
2 IHC to be more sensitive and robust in cases of chronic-active
hepatitis E, it can represent a valuable ancillary tool for path-
ologists dealing with liver biopsies from immunocompromised
patients. Last but not least, IHC methods are low cost and have
a shorter turnaround time.
As illustrated in Figures 1 and 3, the ORF 2 antibody
displayed a different extent of immunohistochemical pos-
itivity depending on the immune status of the patient.
Although liver biopsies from immunocompetent individuals
generally showed fewer, and in some cases only single scat-
tered positive hepatocytes, those from immunocompromised
patients usually displayed larger and often conﬂuent areas of
positive hepatocytes. In addition to already previously
described cytoplasmic and canalicular staining patterns of
ORF 2,64,66 we could detect a previously nondescribed
nuclear staining pattern in our study, which indicates that
this capsid protein may interact with nuclear components.
In summary, ancillary tools for tissue-based HEV
diagnostics available nowadays are applicable in daily rou-
tine diagnostics.
EXTRAHEPATIC MANIFESTATIONS OF
HEPATITIS E VIRUS INFECTION
Finally, although the HEV is primarily hepatotropic, it is
well documented that it also infects nonhepatocytic cells, and
extrahepatic manifestations of HEV are increasingly being
recognized.67 These might be caused directly or indirectly, that
is, immune-mediated, and are extensively described for neu-
rological manifestations such as neuralgic amyotrophy, neu-
ritis, and Guillain-Barré syndrome,68–71 but also include
hematological abnormalities including lymphocytosis or lym-
phopenia, and thrombocytopenia.70,72
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FIGURE 3. Histopathology of autochthonous hepatitis E (HEV genotype 3 infection) in immunocompromised individuals. A, Liver biopsy
of a male patient with chronic hepatitis E (HEV genotype 3 infection) after liver transplantation. Note portal and lobular inflammation and
some lobular disarray. Scale bar: 250 μm. B, High power view displaying predominantly portal inflammation and piecemeal necrosis with
numerous apoptotic hepatocytes (black arrowheads). Scale bar: 100 μm. C, Portal, periportal, and pericentral fibrosis. Sirius red stain,
scale bar: 250 μm. D, Immunohistochemistry for HEV open reading frame 2 protein displaying widespread positivity in hepatocytes with
predominately nuclear reactivity (black arrowhead), predominately cytoplasmic reactivity (gray arrowhead), and no reactivity (white
arrowhead). Scale bar: 50 μm. E, Liver biopsy taken in an early phase after infection with HEV. Note unremarkable portal tract with lack of
inflammation. Scale bar: 100 μm. HEV indicates hepatitis E virus.
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SUMMARY AND OUTLOOK
During the last decades, we witnessed a paradigm shift
for hepatitis E which is no longer regarded as a disease
restricted to resources-poor countries, but rather a globally
relevant health problem.73,74 That hepatitis E has been
underreported or misdiagnosed in the past remains without
doubt; however, the awareness for the disease has recently
increased in Europe.5,75 Taking into account the evidence of
hepatitis E in the past,76 and conﬂicting epidemiologic
data,2,77,78 it cannot be excluded that the perception of hep-
atitis E soon will change similarly in the United States. Recent
progress in the development of experimental systems for
hepatitis E,63,64 along with novel molecular ﬁndings on
HEV,14,21 brought not only insight into basic mechanisms of
this virus, but provided also the rational for the development
of ancillary, tissue-based diagnostic tools.16 Given that the
above outlined broad spectrum of hepatitis E histopathologic
patterns signiﬁcantly overlaps with that of hepatitis of other
etiology, in particular non–E viral hepatitis, autoimmune
hepatitis, and drug-induced liver injury, and is determined by
host factors, we expect hepatitis E to remain a challenging
histopathologic diagnosis in the near future. However,
increased awareness of hepatitis E and a low threshold for
applying ancillary tools, that is, HEV RNA testing and/or
IHC for HEV ORF 2 protein, will enable pathologists to
reliably and timely reach the correct diagnosis.
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